Tokyo, Nov. 8 -- UMIN Clinical Trials Registry (UMIN-CTR) received information related to the study (UMIN000059686) titled 'Treatment Preference Study of Patients with Non-Muscle Invasive Bladder Cancer in Japan' on Nov. 7.
Study Type:
Observational
Primary Sponsor:
Institute - Pfizer Japan Inc.
Condition:
Condition - high-risk non-muscle-invasive bladder cancer (HR-NMIBC)
Classification by malignancy - Malignancy
Genomic information - NO
Objective:
Narrative objectives1 - This study aims to quantify patients' preferences for attributes of investigational ICI agents used in combination with BCG as alternatives to the SOC, BCG alone, for treating patients with HR-NMIBC in Japan.
Basic objectives2 - Others
Eligibility:
Age-lower limit -...